Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 02, 2005. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific director transaction rather than a financial performance report.
Material Changes
The material change disclosed is a transaction involving Dr. L. Shapiro, a Director. The Administrators of the GlaxoSmithKline Scientific Advisory Board Share Allocation Plan purchased 307 American Depository Shares (ADS) for Dr. Shapiro. The transaction occurred on July 29, 2005, at a price of $47.77 per ADS, pursuant to share election arrangements for the Scientific Advisory Board.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the director's share purchase in accordance with Disclosure rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the total number of ADS held by Dr. L. Shapiro following this purchase.
- Confirm the specific terms of the Scientific Advisory Board Share Allocation Plan.
- Check for any other concurrent director transactions not detailed in this specific notification.